From: Interleukin-37: associations of plasma levels and genetic variants in gout
Control subjects (N = 50) | Asymptomatic hyperuricemia patients (N = 74) | Intercritical gout patients (N = 200) | Acute gouty flare patients (N = 18) | Chronic tophaceous gout patients (N = 30) | Fisher’s test p-value | ||||||
N | % | N | % | N | % | N | % | N | % | ||
Sex M/F | 12/38 | 24.0/76.0 | 54/20 | 73.0/27.0 | 179/21 | 89.5/10.5 | 18/0 | 100.0/0.0 | 28/2 | 93.3/6.7 | < 0.0001 |
Familial occurrence | Not collected | 26 | 40.0 | 79 | 41.1 | 9 | 50.0 | 12 | 42.9 | 0.8820 | |
No treatment | 50 | 100.0 | 27 | 41.5 | 16 | 8.6 | 3 | 18.8 | 6 | 21.4 | 0.0005 |
Allopurinol treatment | Not applicable | 38 | 58.5 | 152 | 81.3 | 11 | 68.8 | 18 | 64.3 | ||
Febuxostat treatment | 0 | 0.0 | 19 | 10.2 | 2 | 12.5 | 4 | 14.3 | |||
p.Q141K, MAF | 8 | 8.2 | 27 | 18.2 | 96 | 24.0 | 6 | 16.7 | 14 | 23.3 | 0.0055 |
IL-37 data available | 50 | 100.00 | 63 | 85.1 | 176 | 88.0 | 18 | 100.00 | 25 | 83.33 | < 0.0001 |
Median (IQR) | Range | Median (IQR) | Range | Median (IQR) | Range | Median (IQR) | Range | Median (IQR) | Range | Kruskal–Wallis test p-value | |
Age of onset, years | Not applicable | 35.0 (31.5) | 11–76 | 40.0 (21.0) | 12–84 | 38.0 (18.0) | 18–61 | 36.0 (21.0) | 9–68 | 0.3236 | |
Current age, years | 46.5 (31.2) | 24–78 | 43.5 (33.2) | 19–78 | 50.0 (22.0) | 19–90 | 47.0 (11.2) | 35–63 | 49.0 (23.2) | 29–73 | 0.1053 |
BMI (N = 46/66/179/17/26)c | 25.6 (5.5) | 17.9–38.5 | 29.0 (6.3) | 21–43.6 | 28.4 (5.9) | 19.3–50 | 28.1 (4.6) | 23.4–32.8 | 28.2 (5.0) | 20.7–38.6 | 0.0001 |
SUA without treatment, μmol/l (N = 50/54/140/12/22)c | 329.0 (117.2) | 208–544 | 458.5 (98.5) | 371–635 | 462.0 (115.8) | 181–685 | 504.0 (105.5) | 406–616 | 461.5 (161.0) | 245–647 | < 0.0001 |
SUA with treatment, μmol/l (N = 0/40/170/14/23)c | Not applicable | 415.5 (144.5) | 207–628 | 360.5 (121.8) | 131–725 | 430.5 (158.8) | 238–579 | 438.0 (125.5) | 167–808 | 0.0017 | |
FE-UAa (N = 0/68/196/17/29) | Not measured | 3.8 (1.9) | 1.7–13.2 | 3.7 (1.6) | 0.8–11.8 | 3.2 (1.1) | 2.1–5.4 | 4.5 (3.0) | 1.2–13.1 | 0.3099 | |
GFR-MDRD, ml/mina (N = 50/45/133/11/17) | 79.0 (20.2) | 45–122 | 86.0 (25.0) | 46–138 | 86.0 (26.0) | 24–132 | 92.0 (13.1) | 31–117 | 81.0 (30.5) | 27.5–130.5 | 0.0864 |
Serum creatinine, μmol/la (N = 50/70/198/18/29) | 71.5 (17.8) | 56–105 | 79.0 (19.5) | 44–132 | 80.8 (17.4) | 48–226 | 82.0 (21.0) | 64–189 | 91.5 (20.5) | 57–179 | 0.0003 |
Max CRPb (N = 50/66/180/18/25)c | 1.3 (2.2) | 0.2–10 | 2.6 (4.2) | 0.1–153.1 | 3.7 (5.7) | 0.2–224.4 | 4.8 (16.8) | 0.5–194.7 | 9.2 (31.8) | 0.2–268 | < 0.0001 |